No article text was recorded for this version.
acquired therapeutic resistance (acquired resistance)
Version 1 of 130 papers33 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib
- Blog: Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma
- Blog: Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
- Blog: Computational Cancer Biology: An Evolutionary Perspective
- Blog: Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC
- Blog: Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
- Blog: Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single-Center Study
- Blog: Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer
- Blog: Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
- Blog: Receptor Tyrosine Kinases: Role in Cancer Progression
- Blog: Neuer Therapieansatz bei refraktärer CLL Arzerra® (Ofatumumab): Neuartiger CD20-Antikörper jetzt zugelassen
- Blog: SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling
- Blog: Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma
- Blog: Protein disulfide isomerase family 6 promotes the imatinib-resistance of renal cell carcinoma by regulation of Wnt3a-Frizzled1 axis
- Blog: Long Non-Coding RNA CRNDE is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling
- Blog: The interaction between ncRNAs and the EGFR signaling pathway in lung cancer
- Blog: Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
- Blog: Conceptual Knowledge Discovery in Databases for Drug Combinations Predictions in Malignant Melanoma
- Blog: Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors
- Blog: All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells
- Blog: SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma
- Blog: Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models
- Blog: The research progress of targeted therapy in acute myeloid leukemia based on bibliometric analysis
- Blog: Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial
- Blog: Overcoming imatinib resistance conferred by the <i>BIM</i> deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides
- Blog: The emerging role of circular RNAs in drug resistance of non-small cell lung cancer
- Blog: Machine learning based personalized drug response prediction for lung cancer patients
- Blog: Oxidized Vitamin C (DHA) Overcomes Resistance to EGFR-targeted Therapy of Lung Cancer through Disturbing Energy Homeostasis
- Blog: Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs
- Blog: A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_acquired_therapeutic_resistance_acquired_a7c8207a,
title = {acquired therapeutic resistance (acquired resistance)},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/acquired-therapeutic-resistance-acquired-resistance/rdr_a7c8207a43fa46b2ad91286ba00c08c8},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-22},
}This exact version (version 1, frozen text):
@misc{lacuna_acquired_therapeutic_resistance_acquired_a7c8207a_v1,
title = {acquired therapeutic resistance (acquired resistance)},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/acquired-therapeutic-resistance-acquired-resistance/rdr_a7c8207a43fa46b2ad91286ba00c08c8/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-22},
}